Utilization of Multiparametric MRI of Prostate in Patients under Consideration for or Already in Active Surveillance: Correlation with Imaging Guided Target Biopsy.
PI-RADS score
active surveillance
imaging-guided target prostate biopsy
multiparametric MRI
prostate cancer
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
29 Jun 2020
29 Jun 2020
Historique:
received:
20
05
2020
revised:
24
06
2020
accepted:
25
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
This study sought to assess the value of multiparametric magnetic resonance image (mp-MRI) in patients with a prostate cancer (PCa) Gleason score of 6 or less under consideration for or already in active surveillance and to determine the rate of upgrading by target biopsy. Three hundred and fifty-four consecutive men with an initial transrectal ultrasound-guided (TRUS) biopsy-confirmed PCa Gleason score of 6 or less under clinical consideration for or already in active surveillance underwent mp-MRI and were retrospectively reviewed. One hundred and nineteen of 354 patients had cancer-suspicious regions (CSRs) at mp-MRI. Each CSR was assigned a Prostate Imaging Reporting and Data System (PI-RADS) score based on PI-RADS v2. One hundred and eight of 119 patients underwent confirmatory imaging-guided biopsy for CSRs. Pathology results including Gleason score (GS) and percentage of specimens positive for PCa were recorded. Associations between PI-RADS scores and findings at target biopsy were evaluated using logistic regression. At target biopsy, 81 of 108 patients had PCa (75%). Among them, 77 patients had upgrading (22%, 77 of 354 patients). One hundred and forty-six CSRs in 108 patients had PI-RADS 3
Identifiants
pubmed: 32610595
pii: diagnostics10070441
doi: 10.3390/diagnostics10070441
pmc: PMC7400343
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
AJR Am J Roentgenol. 2017 Jan;208(1):131-139
pubmed: 27726415
J Magn Reson Imaging. 2013 May;37(5):1035-54
pubmed: 23606141
J Clin Oncol. 2010 Jan 1;28(1):126-31
pubmed: 19917860
Eur Urol. 2012 Nov;62(5):902-9
pubmed: 22325447
BJU Int. 2011 Oct;108(8 Pt 2):E171-8
pubmed: 21426475
Radiology. 2008 Dec;249(3):900-8
pubmed: 19011187
Eur Urol. 2011 Apr;59(4):477-94
pubmed: 21195536
J Urol. 2017 Mar;197(3 Pt 1):640-646
pubmed: 27613356
Eur Urol. 2017 Apr;71(4):517-531
pubmed: 27568655
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Ann Intern Med. 2012 Apr 17;156(8):591-5
pubmed: 22351514
Invest Radiol. 2014 Mar;49(3):165-72
pubmed: 24220253
J Urol. 2011 Oct;186(4):1281-5
pubmed: 21849184
J Urol. 2008 Nov;180(5):1964-7; discussion 1967-8
pubmed: 18801515
J Urol. 2012 Apr;187(4):1247-52
pubmed: 22335871
J Urol. 2013 Jan;189(1):86-91
pubmed: 23158413
Eur Urol. 2009 Jun;55(6):1321-30
pubmed: 19286302
Eur Radiol. 2012 Apr;22(4):746-57
pubmed: 22322308
J Urol. 2011 Nov;186(5):1818-24
pubmed: 21944089
J Urol. 2017 Sep;198(3):575-582
pubmed: 28373135
Eur Urol. 2010 Jul;58(1):90-5
pubmed: 19875227
Radiology. 2011 Jun;259(3):775-84
pubmed: 21436085
Urology. 2009 Nov;74(5):1094-9
pubmed: 19773038
J Clin Oncol. 2011 Jun 1;29(16):2185-90
pubmed: 21464416
Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E853-8
pubmed: 26788234
AJR Am J Roentgenol. 2014 Feb;202(2):343-51
pubmed: 24450675
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
AJR Am J Roentgenol. 2007 Aug;189(2):323-8
pubmed: 17646457
Eur Urol. 2014 Apr;65(4):809-15
pubmed: 23523537
Cancer. 1993 Feb 1;71(3 Suppl):933-8
pubmed: 7679045
Radiology. 2006 Jun;239(3):784-92
pubmed: 16569788
J Urol. 2009 Nov;182(5):2274-8
pubmed: 19758635
J Clin Oncol. 2011 Jul 10;29(20):2795-800
pubmed: 21632511
J Urol. 2012 Nov;188(5):1732-8
pubmed: 23017866